risankizumab

Details

Files
Generic Name:
risankizumab
Project Status:
Complete
Therapeutic Area:
Psoriasis, moderate to severe plaque
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
Skyrizi
Project Line:
Reimbursement Review
Project Number:
SR0583-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Reimburse in a manner similar to other biologics for the treatment of moderate-to-severe plaque psoriasis. Treatment should be discontinued if a response (PASI75) to treatment with risankizumab has not been demonstrated after 16 weeks.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Psoriasis, moderate to severe plaque
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedSeptember 19, 2018
Patient group input closedNovember 08, 2018

Clarification:

- Patient input submission received from Arthritis Consumer Experts, Canadian Psoriasis Network (CPN), Canadian Skin Patient Alliance (CSPA) and the Canadian Association of Psoriasis Patients (CAPP)

Patient input summary sent for review to patient input groupsNovember 15, 2018
Patient group comments on input summary closedNovember 22, 2018

Clarification:

- Patient input summary feedback received

Submission receivedOctober 22, 2018
Submission accepted for reviewNovember 05, 2018
Review initiatedNovember 06, 2018
Draft CADTH review report(s) sent to sponsorJanuary 25, 2019
Comments from sponsor on draft CADTH review report(s) receivedFebruary 05, 2019
Redaction requests from sponsor on draft CADTH review report(s) receivedFebruary 12, 2019
CADTH review team's comments on draft CADTH review report(s) sent to sponsorMarch 08, 2019
Canadian Drug Expert Committee (CDEC) meetingMarch 20, 2019

Clarification:

CDEC recommendation held pending receipt of NOC and evaluation of the finalized submission requirements.

CDEC recommendation & redacted CADTH review report(s) sent to sponsor and drug plansMay 02, 2019
Embargo period ended and validation of redacted CADTH review report(s) receivedMay 16, 2019
CDEC Final Recommendation issued to sponsor and drug plansMay 24, 2019
CDEC Final Recommendation postedMay 28, 2019
Final CADTH review report(s) postedJune 24, 2019